Drugs / CD19/BCMA Targeted CAR T-cells
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT04603872 | Nov 2020 → Nov 2023 overdue | acute lymphoblastic leukemia, plasma cell myeloma | Zhejiang University | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19/BCMA Targeted CAR T-cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04603872 ↗ |
| Modality | Cell therapy | “CD19/BCMA-targeted CAR-T Cells” NCT04603872 ↗ |
| Route | Intravenous | “Each subject receive CS1 Targeted CAR T-cells by intravenous infusion.” NCT04603872 ↗ |